FDA Grants Fast Track Designation to Emerging Agent for Brain PET Imaging
Currently being evaluated in a phase 2b clinical trial, the 18F-RAD101 PET imaging agent garnered the FDA’s fast track designation for distinguishing between recurrent disease and treatment impact for brain metastases derived from solid tumors.
The Food and Drug Administration (FDA) has issued a fast track designation for the 18F-RAD101 positron emission tomography (PET) imaging agent, which may help differentiate between treatment impacts on brain metastases and disease recurrence.
Radiopharm Theranostics, the developer of the PET agent, said 18F-RAD101 targets the multi-enzyme protein fatty acid synthase, which can be overexpressed in cerebral metastases and other solid tumors.
The 18F-RAD101 agent is currently being evaluated in a phase 2b multicenter clinical trial involving patients with recurrent brain metastases originating from solid tumors with different origins, according to Radiopharm Theranostics.
“The FDA’s fast track designation for RAD101 highlights the seriousness of recurrent brain metastases as a condition and the unmet medical need for innovative products that can differentiate between tumor recurrence and radiation necrosis or pseudo progression,” noted Riccardo Canevari, the CEO and managing director of Radiopharm Theranostics. “RAD101 represents a promising advancement in improving diagnostic precision for brain metastases, offering hope for more effective clinical decision-making in the over 300,000 patients diagnosed annually in the U.S.”
Recent Videos
Related Content
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Article
Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025Podcast
In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Article
Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025Article
For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025Article
For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
